{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:29:54Z","timestamp":1789266594585,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bmc.2017.12.031","type":"journal-article","created":{"date-parts":[[2017,12,24]],"date-time":"2017-12-24T00:08:53Z","timestamp":1514074133000},"page":"647-660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors"],"prefix":"10.1016","volume":"26","author":[{"given":"Akira","family":"Kaieda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6651-6144","authenticated-orcid":false,"given":"Masashi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4650-789X","authenticated-orcid":false,"given":"Takafumi","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Unno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Itono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terufumi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruki","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Shirasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyorgy","family":"Snell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Bragstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Ching","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Uchikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Miwatashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2017.12.031_b0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0898-6568(97)00042-9","article-title":"Stress-activated protein kinases: activation, regulation and function","volume":"9","author":"Paul","year":"1997","journal-title":"Cell Signal"},{"key":"10.1016\/j.bmc.2017.12.031_b0010","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/372739a0","article-title":"A protein kinase involved in the regulation of inflammatory cytokine biosynthesis","volume":"372","author":"Lee","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2017.12.031_b0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-5793(99)01717-2","article-title":"The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from TNF-\u03b1 or IL-1\u03b2-stimulated rheumatoid synovial fibroblasts","volume":"465","author":"Suzuki","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bmc.2017.12.031_b0020","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1021\/cr000241p","article-title":"MAP Kinases","volume":"101","author":"Chen","year":"2001","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2017.12.031_b0025","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1074\/jbc.270.13.7420","article-title":"Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine","volume":"270","author":"Raingeaud","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2017.12.031_b0030","doi-asserted-by":"crossref","first-page":"R1140","DOI":"10.1186\/ar1797","article-title":"Tumour necrosis factor activates the mitogen-activated protein kinases p38\u03b1 and erk in the synovial membrane in vivo","volume":"7","author":"G\u00f6rtz","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bmc.2017.12.031_b0035","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/1529-0131(200011)43:11<2501::AID-ANR18>3.0.CO;2-K","article-title":"Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis","volume":"43","author":"Schett","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bmc.2017.12.031_b0040","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrd1177","article-title":"P38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases","volume":"2","author":"Kumar","year":"2003","journal-title":"Nature Rev Drug Discov"},{"key":"10.1016\/j.bmc.2017.12.031_b0045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.drudis.2007.04.005","article-title":"Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development","volume":"12","author":"Fitzgerald","year":"2007","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2017.12.031_b0050","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.drudis.2014.11.003","article-title":"Emerging therapeutic strategies in COPD","volume":"20","author":"Babu","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2017.12.031_b0055","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1021\/jm9012906","article-title":"Selective p38\u03b1 inhibitors clinically evaluated for the treatment of chronic inflammatory disorders","volume":"53","author":"Goldstein","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.12.031_b0060","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/cmdc.201100439","article-title":"Discovery and characterization of atropisomer PH-797804, a p38 MAP kinase inhibitor, as a clinical drug candidate","volume":"7","author":"Xing","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmc.2017.12.031_b0065","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1016\/j.bmcl.2011.04.121","article-title":"Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase","volume":"21","author":"Selness","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2017.12.031_b0070","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.bmcl.2010.02.047","article-title":"Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase","volume":"20","author":"Walker","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2017.12.031_b0075","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1016\/j.bmc.2014.05.045","article-title":"Design and synthesis of 5-[(2-chloro-6-fluorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP kinase with reduced side effects based on the antidrug concept","volume":"22","author":"Hasumi","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2017.12.031_b0080","doi-asserted-by":"crossref","first-page":"7772","DOI":"10.1021\/jm3008008","article-title":"Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor","volume":"55","author":"Asano","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.12.031_b0085","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1016\/j.bmcl.2015.06.036","article-title":"Synthesis and biological evaluation of N-cyclopropylbenzamide-benzophenone hybrids as novel and selective p38 mitogen activated protein kinase (MAPK) inhibitors","volume":"25","author":"Heo","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2017.12.031_b0090","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.bbrc.2016.06.111","article-title":"A novel p38 mitogen activated protein kinase (MAPK) specific inhibitor suppresses respiratory syncytial virus and influenza A virus replication by inhibiting virus-induced p38 MAPK activation","volume":"477","author":"Choi","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmc.2017.12.031_b0095","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.2174\/092986705774462914","article-title":"MAP Kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38\u03b1 protein","volume":"12","author":"Lee","year":"2005","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2017.12.031_b0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0014-5793(95)00357-F","article-title":"SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1","volume":"364","author":"Cuenda","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bmc.2017.12.031_b0105","unstructured":"Mavunkel BJ, Chakravarty S, Perumattam J, Dugar S, Lu Q, Liang, X. Preparation of 5-[4-Benzylpiperidinyl(piperazinyl)]-indolecarboxamides as Inhibitors of p38 Kinase. WO2000071535; 2000."},{"key":"10.1016\/j.bmc.2017.12.031_b0110","first-page":"1205","article-title":"SCIO-469 Scios Inc","volume":"5","author":"Nikas","year":"2004","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1016\/j.bmc.2017.12.031_b0115","first-page":"1070","article-title":"VX-745. Vertex Pharmaceuticals","volume":"2","author":"Haddad","year":"2001","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1016\/j.bmc.2017.12.031_b0120","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2174\/1568026054985876","volume":"5","author":"Natarajan","year":"2005","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2017.12.031_b0125","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1021\/jm020057r","article-title":"Pyrazole urea\u2013based inhibitors of p38 MAP kinase: from lead compound to clinical candidate","volume":"45","author":"Regan","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.12.031_b0130","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1021\/jm050165o","article-title":"Novel Inhibitor o p38 MAP kinase as an anti-TNF-\u03b1 drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent","volume":"48","author":"Miwatashi","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.12.031_b0135","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1248\/cpb.53.410","article-title":"Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as p38 MAP kinase inhibitors","volume":"53","author":"Miwatashi","year":"2005","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.bmc.2017.12.031_b0140","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1107\/S090744491201997X","article-title":"X-ray structure of p38a bound to TAK-715: comparison with three classic inhibitors","volume":"68","author":"Azevedo","year":"2012","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.bmc.2017.12.031_b0145","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1021\/jm900521k","article-title":"Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia","volume":"52","author":"Verhoest","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.12.031_b0150","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1359-6446(05)03580-4","article-title":"High throughput P450 inhibition screens in early drug discovery","volume":"10","author":"Zlokarnik","year":"2005","journal-title":"Drug Discov Today"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089617317819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089617317819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:52:02Z","timestamp":1760835122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089617317819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0968089617317819"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2017.12.031","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2017.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}